Article

Promising Hepatitis C Drugs Highlight AJPB Week in Review

Author(s):

AJPB staff

Top articles of the week from The American Journal of Pharmacy Benefits.

Related Videos
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com
Image Credit: © Cavan - stock.adobe.com
Child with cancer -- Image credit: Alexis Scholtz/peopleimages.com | stock.adobe.com
Image Credit: © Rawpixel.com - stock.adobe.com
Image Credit: © RandyJay - stock.adobe.com
WCLC, lung cancer, NSCLC
MARIPOSA Study: Long-Term Outcomes and Next Steps for Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC
The EMPOWER-Lung 1 Trial: Five-Year Outcomes of Cemiplimab Monotherapy in Advanced NSCLC
Related Content
Image Credit: © Jasmine - stock.adobe.com
October 21st 2024

Momelotinib Demonstrates Efficacy, Safety Compared With Ruxolitinib for Treatment of Myelofibrosis

Alexandra Gerlach, Associate Editor
Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment
September 26th 2024

Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment

Health care professional and patient -- Image credit: thatinchan | stock.adobe.comHealth care professional and patient -- Image credit: thatinchan | stock.adobe.com
October 21st 2024

Review of 3 Alternative Pathways to Access Non–FDA-Approved Drugs

Emily Hennes, PharmD, BCOP Berrie Child, PharmD, BCOP Stefanie Conley, PharmD, BCOP Dina Dumercy McHenry, PharmD, MBA, BCOP, CSSGB Sarah Lentz, BCOP Camille Smith, PharmD, DPLA, CCRP Jennifer Murphy, PharmD, BCOP
Pharmacy Focus- Oncology Edition: Delayed Breast Cancer Screenings
August 29th 2024

Pharmacy Focus- Oncology Edition: Delayed Breast Cancer Screenings

Woman holding pink ribbon for breast cancer awareness -- Image credit: marina_li_1 | stock.adobe.com
October 20th 2024

RK-33 May Be Significant in Treatment of Breast Cancer Bone Metastasis

Gillian McGovern, Assistant Editor
Image Credit: © Crystal light - stock.adobe.com
Published: October 18th 2024 | Updated: October 18th 2024

Zolbetuximab-clzb Receives FDA Approval for Treatment of Advanced Gastric and GEJ Adenocarcinoma

Alexandra Gerlach, Associate Editor